Article

Selective COX-2 Inhibitors, NSAIDs, aspirin, and myocardial infarction.

Archives of Internal Medicine (Impact Factor: 13.25). 06/2002; 162(10):1091-2.
Source: PubMed
0 Followers
 · 
71 Views
  • The Lancet 12/2002; 360(9346):1700-1. DOI:10.1016/S0140-6736(02)11635-7 · 45.22 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The development of cyclooxygenase (COX)-2-selective inhibitors represents a major advance in the management of chronic pain and inflammation that may satisfy an unmet medical need for agents with improved gastrointestinal (GI) safety. This article is a review of the pharmacology, clinical efficacy, and safety of COX-2-selective inhibitors in the managed healthcare setting. The efficacy of COX-2-selective inhibitors in relieving chronic pain from osteoarthritis and rheumatoid arthritis is comparable to that of traditional nonsteroidal anti-inflammatory drugs (NSAIDs). However, the occurrence of GI complications may be less frequent in patients who receive COX-2-selective inhibitors than in patients receiving traditional NSAIDs. Thus, the use of COX-2-selective inhibitors for the management of chronic pain may reduce overall costs and provide an alternative with an improved safety profile compared with traditional NSAIDs.
    The American journal of managed care 12/2002; 8(17 Suppl):S502-17. · 2.17 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed for musculoskeletal injuries because the conditions are believed to be inflammatory in nature. However, because inflammation is a necessary component in the healing process, decreasing inflammation may prove counterproductive. Also, many tendon injuries called 'tendinitis' are, in fact, degenerative and not inflammatory conditions. An analysis of the pathophysiology and healing of musculoskeletal injuries questions the use of NSAIDs in many treatment protocols. Because NSAIDs have profound side effects, they should not automatically be the first choice for treating musculoskeletal injuries.
    The Physician and sportsmedicine 01/2003; 31(1):35-52. DOI:10.3810/psm.2003.01.160 · 1.49 Impact Factor
Show more

Preview

Download
2 Downloads
Available from